Table 6 Publications on late toxicity of radiotherapy of the prostate bed with or without pelvic irradiation
Median follow-up | Late grade 1 | Late grade 2 | Late grade 3 | Late grade 4 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
GI | GU | GI | GU | GI | GU | GI | GU | |||
Bolla et al. [1] | 3D-CRT prostate bed 66.0 Gy | 60 months | - | - | - | - | 4.2% | 0% | 0% | |
Bolla et al. [12] | 3D-CRT prostate bed 66.0 Gy | 127 months | - | - | - | - | 5.3% | 0% | 0% | |
Wiegel et al. [3] | 3D-CRT prostate bed 66.60 Gy | 54 months | - | - | 1.4% | 2.0% | - | 0.5% | 0% | 0% |
Bellavita et al. [13] | 3D-CRT prostate bed 66.6 Gy | 56 months | 7.1% (G1/2) | 9.9% (G1/2) | - | - | 0.5% | 5.5% | 0% | 0% |
Ost et al. [18] | IMRT/3D-CRT prostate bed 69.1 Gy | 60 months | ∼ 28% | ∼ 34% | ∼ 5% | ∼ 17% | < 1% | 10% | 0% | 0% |
Current trial | IMRT WPRT 51 Gy + boost prostate bed 68 Gy | 24 months | 7.5% | 22.5% | 10.0% | 5.0% | 5.0% | 0% | 0% | 0% |
Deville et al.[15] | IMRT WPRT 45 Gy Gy + boost prostate bed 70.2 Gy | 26 months | 11% | 50% | 3% | 17% | 0% | 11% | 0% | 0% |
Aizer et al.[16] | 3D-CRT WPRT 45 Gy + IMRT boost prostate 75.6 Gy | 30 months | 2.9% | 1.5% | 4.4% | 1.5% | 1.5% | 0% | 0% | 0% |
Roach et al.[4] | 3D-CRT WPRT 45 Gy + boost prostate 70.2 Gy | - | - | - | - | - | 4.3% (G3/4) | 3.0% (G3/4) | - | - |